Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 8Sarcoma 3Kidney Neoplasms 3Carcinoma, Renal Cell 3Wilms Tumor 2Testicular Neoplasms 2Teratoma 2Ovarian Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Liver Neoplasms 2Central Nervous System Neoplasms 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Testicular Germ Cell Tumor 1Seminoma 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Prostatic Diseases 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Germ Cell Cancer 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms, Glandular and Epithelial 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Etoposide 17Filgrastim 16Carboplatin 16Ifosfamide 15Peripheral Blood Stem Cell Transplantation 14Cisplatin 14Paclitaxel 12Cyclophosphamide 8Bleomycin 7Radiotherapy 6pegfilgrastim 4Thiotepa 4Flow Cytometry 4etoposide phosphate 3Immunologic Techniques 3sargramostim 2aldesleukin 2Vinblastine 2Temozolomide 2Polymerase Chain Reaction 2Microarray Analysis 2Methylprednisolone 2Magnetic Resonance Spectroscopy 2Immunohistochemistry 2Granisetron 2Gemcitabine 2Dexamethasone 2Busulfan 2Amplified Fragment Length Polymorphism Analysis 2Alemtuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Testicular Germ Cell Tumor × ixabepilone × Genitourinary × Clear all
NCT00070096 2013-06-24

Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors

National Cancer Institute (NCI)

Phase 2 Completed
29 enrolled
CNSGenitourinaryGynecologic

Testicular Germ Cell Tumor, Ovarian Neoplasms, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Carcinoma, Embryonal, Seminoma, Endodermal Sinus Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡